Therapeutic potential of functional selectivity in the treatment of heart failure

Gitte Lund Christensen, Mark Aplin, Jakob Lerche Hansen

Publikation: Bidrag til tidsskriftTidsskriftsartikelForskningpeer review

Abstract

Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with "functional selectivity," acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.

OriginalsprogEngelsk
TidsskriftTrends in Cardiovascular Medicine
Vol/bind20
Udgave nummer7
Sider (fra-til)221-7
Antal sider7
ISSN1050-1738
DOI
StatusUdgivet - okt. 2010
Udgivet eksterntJa

Citationsformater